Enlivex Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
0.6217
+0.0037 (0.60%)
At close: Jun 18, 2026, 4:00 PM EDT
0.6399
+0.0182 (2.93%)
After-hours: Jun 18, 2026, 6:13 PM EDT
Enlivex Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw record net income and EPS, driven by treasury gains from prediction markets, especially RAIN tokens. Clinical progress continued with FDA clearance for a Phase IIb osteoarthritis trial, while new financing and share repurchase initiatives support future growth.
-
Top-line phase II-A data show Allocetra achieved a 72% pain reduction over placebo in primary knee osteoarthritis patients aged 60+, with efficacy increasing in older groups and a favorable safety profile. The company plans a phase II-B trial, is initiating partnership discussions, and expects its competitive pricing to support broad adoption.